The Max Foundation shared a post on LinkedIn:
“Generic cancer medicines can be a powerful tool for expanding access to treatment, especially in low- and middle-income countries, where cost remains a major barrier for many patients.
A recently published review by Dr. Aniruddha Burli and Max partner physician Dr. Hemant Malhotra highlights both the benefits and risks of generic drugs for blood cancers. These treatments can help make lifesaving medicines more affordable and available to patients globally, but only when supported by safeguards to ensure they are safe, high-quality, and carefully monitored.
With the right systems in place, quality-assured generics can help more patients receive the lifesaving treatment they need.”
Title: Benefits and perils of generic drugs for hematologic neoplasms and their use in low- and middle-income countries: a narrative review
Authors: Hemant Malhotra, Aniruddha Burli
Read the Full Article on Blood Global Hematology
More posts about The Max Foundation.
